In the event that the current inoculation is ineffective against the newer strain, Pfizer’s CEO Albert Bourla said Monday that the company has already begun developing a version of its Covid-19 vaccine that particularly targets the new Omicron variant.
According to Bourla, his company began testing the current vaccine against the Omicron version on Friday, which was initially discovered in South Africa and has sparked worries of a global Covid-19 outbreak.
